首页 > 最新文献

Current Clinical Microbiology Reports最新文献

英文 中文
Selection of Relevant Bacterial Strains for Novel Therapeutic Testing: a Guidance Document for Priority Cystic Fibrosis Lung Pathogens 新型治疗试验相关菌株的选择:肺囊性纤维化优先病原菌的指导文件
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-10-14 DOI: 10.1007/s40588-022-00182-2
E. Mahenthiralingam, R. Weiser, R. Floto, J. Davies, J. Fothergill
{"title":"Selection of Relevant Bacterial Strains for Novel Therapeutic Testing: a Guidance Document for Priority Cystic Fibrosis Lung Pathogens","authors":"E. Mahenthiralingam, R. Weiser, R. Floto, J. Davies, J. Fothergill","doi":"10.1007/s40588-022-00182-2","DOIUrl":"https://doi.org/10.1007/s40588-022-00182-2","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"33 - 45"},"PeriodicalIF":5.2,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41773807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Microbial Interplay in Skin and Chronic Wounds 皮肤和慢性伤口中的微生物夹层
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-08-06 DOI: 10.1007/s40588-022-00180-4
Chandni Sachdeva, K. Satyamoorthy, T. S. Murali
{"title":"Microbial Interplay in Skin and Chronic Wounds","authors":"Chandni Sachdeva, K. Satyamoorthy, T. S. Murali","doi":"10.1007/s40588-022-00180-4","DOIUrl":"https://doi.org/10.1007/s40588-022-00180-4","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"21 - 31"},"PeriodicalIF":5.2,"publicationDate":"2022-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44960008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Correction to: Germination of a Field: Women in Candida albicans Research 修正:一个领域的萌芽:女性在白色念珠菌研究
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-03-10 DOI: 10.1007/s40588-022-00176-0
Faith M. Anderson, Elizabeth J. Polvi, Amanda O. Veri, Teresa R. O’Meara
{"title":"Correction to: Germination of a Field: Women in Candida albicans Research","authors":"Faith M. Anderson, Elizabeth J. Polvi, Amanda O. Veri, Teresa R. O’Meara","doi":"10.1007/s40588-022-00176-0","DOIUrl":"https://doi.org/10.1007/s40588-022-00176-0","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"1 1","pages":"1"},"PeriodicalIF":5.2,"publicationDate":"2022-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47701917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists 更正:球虫研究综述、领域内的突出问题和女科学家的贡献
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-03-01 DOI: 10.1007/s40588-022-00177-z
M. Gorris, M. V. Van Dyke, A. Carey, Paris S. Hamm, Heather L. Mead, J. Uehling
{"title":"Correction to: A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists","authors":"M. Gorris, M. V. Van Dyke, A. Carey, Paris S. Hamm, Heather L. Mead, J. Uehling","doi":"10.1007/s40588-022-00177-z","DOIUrl":"https://doi.org/10.1007/s40588-022-00177-z","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"10 - 10"},"PeriodicalIF":5.2,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47273031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Fungal Infections: from the Fields to the Clinic, Resistant Aspergillus fumigatus and Dermatophyte Species: a One Health Perspective on an Urgent Public Health Problem. 新出现的真菌感染:从田间到临床》,《耐药曲霉菌和皮癣菌种:从单一健康视角看待亟待解决的公共健康问题》,《新出现的真菌感染:从田间到临床》,《耐药曲霉菌和皮癣菌种:从单一健康视角看待亟待解决的公共健康问题》。
IF 3.1 Q2 MICROBIOLOGY Pub Date : 2022-01-01 Epub Date: 2022-09-27 DOI: 10.1007/s40588-022-00181-3
Antonia Langfeldt, Jeremy A W Gold, Tom Chiller

Purpose of review: For this review, we use a One Health approach to examine two globally emerging public health threats related to antifungal drug resistance: triazole-resistant Aspergillus fumigatus infections, which can cause a life-threatening illness in immunocompromised hosts, and antifungal-resistant dermatophytosis, which is an aggressive skin infection caused by dermatophyte molds. We describe the state of current scientific knowledge and outline necessary public health actions to address each issue.

Recent findings: Recent evidence has identified the agricultural use of triazole fungicides as an important driver of triazole-resistant A. fumigatus infections. Antifungal-resistant dermatophyte infections are likely driven by the inappropriate use of antifungal drugs and antibacterial and corticosteroid creams.

Summary: This review highlights the need for a One Health approach to address emerging antifungal resistant infections, emphasizing judicious antifungal use to preserve available treatments; strengthened laboratory capacity to identify antifungal resistance; and improved human, animal, and environmental surveillance to detect emerging resistance, monitor trends, and evaluate the effectiveness of efforts to decrease spread.

综述的目的:在这篇综述中,我们采用 "一体健康 "方法研究了与抗真菌药物耐药性有关的两种全球新出现的公共卫生威胁:耐三唑曲霉菌感染和耐抗真菌皮癣菌病,前者可导致免疫力低下的宿主患上危及生命的疾病,后者则是由皮癣菌引起的一种侵袭性皮肤感染。我们描述了当前的科学知识状况,并概述了解决每个问题所需的公共卫生行动:最近的证据表明,农业中使用三唑类杀菌剂是导致抗三唑类药物的烟曲霉菌感染的重要原因。抗真菌耐药性皮癣菌感染很可能是由于抗真菌药物以及抗菌和皮质类固醇药膏的不当使用造成的。总结:本综述强调了采用 "一体健康 "方法应对新出现的抗真菌耐药性感染的必要性,强调要明智使用抗真菌药物,以保护可用的治疗方法;加强实验室能力,以确定抗真菌耐药性;改进人类、动物和环境监测,以检测新出现的耐药性、监测趋势并评估减少传播的工作成效。
{"title":"Emerging Fungal Infections: from the Fields to the Clinic, Resistant <i>Aspergillus fumigatus</i> and Dermatophyte Species: a One Health Perspective on an Urgent Public Health Problem.","authors":"Antonia Langfeldt, Jeremy A W Gold, Tom Chiller","doi":"10.1007/s40588-022-00181-3","DOIUrl":"10.1007/s40588-022-00181-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>For this review, we use a One Health approach to examine two globally emerging public health threats related to antifungal drug resistance: triazole-resistant <i>Aspergillus fumigatus</i> infections, which can cause a life-threatening illness in immunocompromised hosts, and antifungal-resistant dermatophytosis, which is an aggressive skin infection caused by dermatophyte molds. We describe the state of current scientific knowledge and outline necessary public health actions to address each issue.</p><p><strong>Recent findings: </strong>Recent evidence has identified the agricultural use of triazole fungicides as an important driver of triazole-resistant <i>A. fumigatus</i> infections. Antifungal-resistant dermatophyte infections are likely driven by the inappropriate use of antifungal drugs and antibacterial and corticosteroid creams.</p><p><strong>Summary: </strong>This review highlights the need for a One Health approach to address emerging antifungal resistant infections, emphasizing judicious antifungal use to preserve available treatments; strengthened laboratory capacity to identify antifungal resistance; and improved human, animal, and environmental surveillance to detect emerging resistance, monitor trends, and evaluate the effectiveness of efforts to decrease spread.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"46-51"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10735856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities. 资源有限环境下的全基因组测序:挑战与机遇。
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-01-01 DOI: 10.1007/s40588-022-00183-1
Fredrickson B Wasswa, Kennedy Kassaza, Kirsten Nielsen, Joel Bazira

Purpose of review: The introduction of MinION whole-genome sequencing technology greatly increased and simplified complete genome sequencing in various fields of science across the globe. Sequences have been generated from complex organisms to microorganisms and are stored in genome databases that are readily accessible by researchers. Various new software for genome analysis, along with upgrades to older software packages, are being generated. New protocols are also being validated that enable WGS technology to be rapidly and increasingly used for sequencing in field settings.

Recent findings: MinION WGS technology has been implemented in developed countries due to its advantages: portability, real-time analysis, and lower cost compared to other sequencing technologies. While these same advantages are critical in developing countries, MinION WGS technology is still under-utilized in resource-limited settings.

Summary: In this review, we look at the applications, advantages, challenges, and opportunities of using MinION WGS in resource-limited settings.

综述目的:MinION全基因组测序技术的引入极大地促进和简化了全球各个科学领域的全基因组测序。从复杂生物体到微生物的序列已经产生,并存储在基因组数据库中,便于研究人员访问。各种用于基因组分析的新软件,以及对旧软件包的升级,正在产生。新的协议也正在得到验证,使WGS技术能够迅速并越来越多地用于现场测序。MinION WGS技术由于其便携性、实时分析和与其他测序技术相比成本更低的优点,已在发达国家实施。虽然这些同样的优势在发展中国家至关重要,但在资源有限的情况下,MinION WGS技术仍未得到充分利用。摘要:在这篇综述中,我们着眼于在资源有限的环境中使用MinION WGS的应用、优势、挑战和机遇。
{"title":"MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities.","authors":"Fredrickson B Wasswa,&nbsp;Kennedy Kassaza,&nbsp;Kirsten Nielsen,&nbsp;Joel Bazira","doi":"10.1007/s40588-022-00183-1","DOIUrl":"https://doi.org/10.1007/s40588-022-00183-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>The introduction of MinION whole-genome sequencing technology greatly increased and simplified complete genome sequencing in various fields of science across the globe. Sequences have been generated from complex organisms to microorganisms and are stored in genome databases that are readily accessible by researchers. Various new software for genome analysis, along with upgrades to older software packages, are being generated. New protocols are also being validated that enable WGS technology to be rapidly and increasingly used for sequencing in field settings.</p><p><strong>Recent findings: </strong>MinION WGS technology has been implemented in developed countries due to its advantages: portability, real-time analysis, and lower cost compared to other sequencing technologies. While these same advantages are critical in developing countries, MinION WGS technology is still under-utilized in resource-limited settings.</p><p><strong>Summary: </strong>In this review, we look at the applications, advantages, challenges, and opportunities of using MinION WGS in resource-limited settings.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"52-59"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9601454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection. 继发真菌合并感染的COVID-19患者何时开始抗真菌治疗。
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2022-01-01 DOI: 10.1007/s40588-022-00184-0
Harnoor Singh Pruthi

Purpose of review: Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management.

Recent findings: The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections.

Summary: As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.

回顾目的:严重急性呼吸道冠状病毒2 (SARS-CoV-2)已经影响了卫生保健服务系统2年多。随着时间的推移,与COVID-19患者合并感染相关的许多问题不断浮出水面。关于COVID-19患者中各种真菌合并感染的报道很多。真菌病原体的严重程度已被认为是这一人群发病率和死亡率的重要原因。认识、理解和系统的方法来管理COVID-19患者的真菌合并感染非常重要。目前还没有指南列举了管理与COVID-19同时发生的真菌感染的分步方法。本文综述了COVID-19患者的真菌合并感染及其逐步筛查和处理。最近的发现:据报道,与COVID-19共存的最常见真菌感染是念珠菌病、曲霉病和毛霉病。据报道,在住院的COVID-19患者中,特别是在重症监护病房的患者中,COVID-19患者中合并感染的发生率要高得多。虽然尚未明确的发病机制,但COVID-19患者的侵袭性真菌感染风险很高。摘要:由于继发性真菌感染在COVID-19患者中一直具有挑战性,因为它们往往影响危重患者或免疫功能低下患者,因此诊断和治疗的延误可能是致命的。在仔细评估患者的免疫状态、药物相互作用和不良反应后,应谨慎开始使用抗真菌药物。优化诊断方法、常规筛查和及时启动抗真菌治疗是成功治疗COVID-19患者真菌感染的关键因素。
{"title":"When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection.","authors":"Harnoor Singh Pruthi","doi":"10.1007/s40588-022-00184-0","DOIUrl":"https://doi.org/10.1007/s40588-022-00184-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management.</p><p><strong>Recent findings: </strong>The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections.</p><p><strong>Summary: </strong>As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"60-68"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia. 哥伦比亚麦德林两个诊所住院的新冠肺炎成年人的生存率和临床特征比较
IF 3.1 Q2 MICROBIOLOGY Pub Date : 2022-01-01 Epub Date: 2022-04-09 DOI: 10.1007/s40588-022-00179-x
Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García

Purpose of review: This study compares the survival and clinical profile of hospitalized adults with COVID-19 in two clinics in the city of Medellín, Colombia, with a prospective study with 198 patients in clinic A and 201 in clinic B. Comparisons were made with chi-square and Mann-Whitney U, factors associated with survival were identified with a Cox regression.

Recent findings: The proportion of deaths was 7.1% in clinic A with a mean survival of 51.9 days (95% CI = 45-59); in clinic B 13.9% of patients died with mean survival of 37.8 days (95% CI = 32-43). The most prevalent comorbidities were hypertension (41.6%), diabetes (23.8%), obesity (15.0%), hypothyroidism (13.0%), dyslipidemia (11.0%), and chronic lung disease (10.8%) with similar proportions in both clinics. There were also differences by the clinic in the most prevalent complications: bacterial pneumonia (18.8%), acute renal failure (14.3%), and encephalopathy (9.5%). There were no differences in the days of hospitalization, mechanical ventilation (clinic A 23.7% and clinic B 29.4%) and admission to the ICU (25.3% in A and 32.3% in B).

Summary: We evidence the heterogeneity of the survival and the clinical profile of the patients who are cared for by two institutions of the same city. These findings demonstrate the need to conduct unique studies for each institution, which poses a significant challenge for hospital epidemiology programs due to the impossibility of extrapolating evidence from other healthcare institutions and the need to implement personalized medicine programs given the clinical diversity of patients hospitalized for COVID-19.

综述目的:本研究比较了哥伦比亚麦德林市两家诊所的COVID-19住院成人患者的存活率和临床概况,其中A诊所收治了198名患者,B诊所收治了201名患者,并进行了前瞻性研究:A诊所的死亡比例为7.1%,平均生存期为51.9天(95% CI = 45-59);B诊所的死亡比例为13.9%,平均生存期为37.8天(95% CI = 32-43)。最常见的合并症是高血压(41.6%)、糖尿病(23.8%)、肥胖(15.0%)、甲状腺功能减退(13.0%)、血脂异常(11.0%)和慢性肺病(10.8%),两家诊所的比例相似。各诊所在最常见并发症方面也存在差异:细菌性肺炎(18.8%)、急性肾功能衰竭(14.3%)和脑病(9.5%)。住院天数、机械通气(A 诊所为 23.7%,B 诊所为 29.4%)和入住重症监护室(A 诊所为 25.3%,B 诊所为 32.3%)方面没有差异。这些研究结果表明,有必要对每个机构进行独特的研究,这对医院流行病学项目提出了重大挑战,因为无法从其他医疗机构推断证据,而且鉴于 COVID-19 住院患者的临床多样性,有必要实施个性化医疗项目。
{"title":"Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia.","authors":"Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García","doi":"10.1007/s40588-022-00179-x","DOIUrl":"10.1007/s40588-022-00179-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>This study compares the survival and clinical profile of hospitalized adults with COVID-19 in two clinics in the city of Medellín, Colombia, with a prospective study with 198 patients in clinic A and 201 in clinic B. Comparisons were made with chi-square and Mann-Whitney <i>U</i>, factors associated with survival were identified with a Cox regression.</p><p><strong>Recent findings: </strong>The proportion of deaths was 7.1% in clinic A with a mean survival of 51.9 days (95% CI = 45-59); in clinic B 13.9% of patients died with mean survival of 37.8 days (95% CI = 32-43). The most prevalent comorbidities were hypertension (41.6%), diabetes (23.8%), obesity (15.0%), hypothyroidism (13.0%), dyslipidemia (11.0%), and chronic lung disease (10.8%) with similar proportions in both clinics. There were also differences by the clinic in the most prevalent complications: bacterial pneumonia (18.8%), acute renal failure (14.3%), and encephalopathy (9.5%). There were no differences in the days of hospitalization, mechanical ventilation (clinic A 23.7% and clinic B 29.4%) and admission to the ICU (25.3% in A and 32.3% in B).</p><p><strong>Summary: </strong>We evidence the heterogeneity of the survival and the clinical profile of the patients who are cared for by two institutions of the same city. These findings demonstrate the need to conduct unique studies for each institution, which poses a significant challenge for hospital epidemiology programs due to the impossibility of extrapolating evidence from other healthcare institutions and the need to implement personalized medicine programs given the clinical diversity of patients hospitalized for COVID-19.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"11-19"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46756479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Chronic Infection in Alzheimer's Disease: Instigators, Co-conspirators, or Bystanders? 慢性感染在阿尔茨海默病中的作用:煽动者、共谋者还是旁观者?
IF 3.1 Q2 MICROBIOLOGY Pub Date : 2021-12-01 Epub Date: 2021-04-24 DOI: 10.1007/s40588-021-00168-6
Lauren Butler, Keenan A Walker

Purpose of review: Herein, we provide a critical review of the clinical and translational research examining the relationship between viral and bacterial pathogens and Alzheimer's disease. In addition, we provide an overview of the biological pathways through which chronic infection may contribute to Alzheimer's disease.

Recent findings: Dementia due to Alzheimer's disease is a leading cause of disability among older adults in developed countries, yet knowledge of the causative factors that promote Alzheimer's disease pathogenesis remains incomplete. Over the past several decades, numerous studies have demonstrated an association of chronic viral and bacterial infection with Alzheimer's disease. Implicated infectious agents include numerous herpesviruses (HSV-1, HHV-6, HHV-7) and various gastric, enteric, and oral bacterial species, as well as Chlamydia pneumonia and multiple spirochetes.

Summary: Evidence supports the association between multiple pathogens and Alzheimer's disease risk. Whether these pathogens play a causal role in Alzheimer's pathophysiology remains an open question. We propose that the host immune response to active or latent infection in the periphery or in the brain triggers or accelerates the Alzheimer's disease processes, including the accumulation of amyloid-ß and pathogenic tau, and neuroinflammation. While recent research suggests that such theories are plausible, additional longitudinal studies linking microorganisms to Aß and phospho-tau development, neuroinflammation, and clinically defined Alzheimer's dementia are needed.

综述的目的:在此,我们对研究病毒和细菌病原体与阿尔茨海默病之间关系的临床和转化研究进行了重要综述。此外,我们还概述了慢性感染可能导致阿尔茨海默病的生物学途径:阿尔茨海默病导致的痴呆是发达国家老年人致残的主要原因,但人们对促进阿尔茨海默病发病机制的致病因素的了解仍不全面。在过去的几十年中,大量研究表明慢性病毒和细菌感染与阿尔茨海默病有关。涉及的感染病原体包括多种疱疹病毒(HSV-1、HHV-6、HHV-7)和多种胃肠道和口腔细菌,以及肺炎衣原体和多种螺旋体。这些病原体是否在阿尔茨海默病的病理生理学中起着因果作用仍是一个未决问题。我们提出,宿主对外周或大脑中活跃或潜伏感染的免疫反应触发或加速了阿尔茨海默病的发病过程,包括淀粉样蛋白-ß和致病性 tau 的积累以及神经炎症。虽然最近的研究表明这种理论是可信的,但还需要进行更多的纵向研究,将微生物与 Aß 和磷酸化 tau 的发展、神经炎症和临床定义的阿尔茨海默氏症痴呆症联系起来。
{"title":"The Role of Chronic Infection in Alzheimer's Disease: Instigators, Co-conspirators, or Bystanders?","authors":"Lauren Butler, Keenan A Walker","doi":"10.1007/s40588-021-00168-6","DOIUrl":"10.1007/s40588-021-00168-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Herein, we provide a critical review of the clinical and translational research examining the relationship between viral and bacterial pathogens and Alzheimer's disease. In addition, we provide an overview of the biological pathways through which chronic infection may contribute to Alzheimer's disease.</p><p><strong>Recent findings: </strong>Dementia due to Alzheimer's disease is a leading cause of disability among older adults in developed countries, yet knowledge of the causative factors that promote Alzheimer's disease pathogenesis remains incomplete. Over the past several decades, numerous studies have demonstrated an association of chronic viral and bacterial infection with Alzheimer's disease. Implicated infectious agents include numerous herpesviruses (HSV-1, HHV-6, HHV-7) and various gastric, enteric, and oral bacterial species, as well as <i>Chlamydia pneumonia</i> and multiple spirochetes.</p><p><strong>Summary: </strong>Evidence supports the association between multiple pathogens and Alzheimer's disease risk. Whether these pathogens play a causal role in Alzheimer's pathophysiology remains an open question. We propose that the host immune response to active or latent infection in the periphery or in the brain triggers or accelerates the Alzheimer's disease processes, including the accumulation of amyloid-ß and pathogenic tau, and neuroinflammation. While recent research suggests that such theories are plausible, additional longitudinal studies linking microorganisms to Aß and phospho-tau development, neuroinflammation, and clinically defined Alzheimer's dementia are needed.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"8 4","pages":"199-212"},"PeriodicalIF":3.1,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849576/pdf/nihms-1716713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39940433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Introduction to Current Trends in Meat Microbiology and Hygiene 介绍肉类微生物学和卫生的最新趋势
IF 5.2 Q2 MICROBIOLOGY Pub Date : 2021-09-12 DOI: 10.1007/s40588-021-00175-7
S. Johler, C. Guldimann
{"title":"An Introduction to Current Trends in Meat Microbiology and Hygiene","authors":"S. Johler, C. Guldimann","doi":"10.1007/s40588-021-00175-7","DOIUrl":"https://doi.org/10.1007/s40588-021-00175-7","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"1 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2021-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44749036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Current Clinical Microbiology Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1